64Cu-AMD3100—A novel imaging agent for targeting chemokine receptor CXCR4
- 15 February 2009
- journal article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry
- Vol. 17 (4), 1486-1493
- https://doi.org/10.1016/j.bmc.2009.01.014
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Quantitation of CXCR4 Expression in Myocardial Infarction Using 99mTc-Labeled SDF-1αJournal of Nuclear Medicine, 2008
- AMD3465, a Novel CXCR4 Receptor Antagonist, Abrogates Schistosomal Antigen-Elicited (Type-2) Pulmonary Granuloma FormationThe American Journal of Pathology, 2006
- Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumorsNuclear Medicine and Biology, 2006
- In vivo evaluation of copper-64-labeled monooxo-tetraazamacrocyclic ligandsNuclear Medicine and Biology, 2004
- The Biology of Chemokines and their ReceptorsAnnual Review of Immunology, 2000
- Efficient One-Pot Synthesis of Jm3100Synthetic Communications, 1998
- A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infectionSeminars in Immunology, 1998
- Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar developmentNature, 1998
- Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4The Journal of Experimental Medicine, 1997
- Efficient production of high specific activity 64Cu using a biomedical cyclotronNuclear Medicine and Biology, 1997